Nexium Capsules Helicobacter Pylori Specific Clinical Experience Investigation

AstraZeneca369 enrolled

Overview

The purpose of this study is to confirm the safety profile / factors which impact safety and efficacy in patients given triple therapy for Helicobacter pylori eradication with Nexium + amoxicillin (AMPC) + clarithromycin (CAM), or Nexium + AMPC + metronidazole (MNZ) in usual post-marketing use.

Nexium capsules Specific Clinical Experience Investigation concerning Helicobacter pylori eradication

Study Type

OBSERVATIONAL

Enrollment

369

Conditions

Gastric Ulcer Duodenal Ulcer Gastric Mucosa-associated Lymphoid Tissue (MALT)Lymphoma Idiopathic Thrombocytopenic Purpura Early Gastric Cancer

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion criteria: * Triple therapy for H.pylori eradication to stomach started after endoscopic treatment for gastric ulcer * Triple therapy for H.pylori eradication to stomach started after endoscopic treatment for duodenal ulcer * Triple therapy for H.pylori eradication to stomach started after endoscopic treatment for gastric MALT lymphoma * Triple therapy for H.pylori eradication to stomach started after endoscopic treatment for idiopathic thrombocytopenic purpura * Triple therapy for H.pylori eradication to stomach started after endoscopic treatment for early gastric cancer Exclusion Criteria: \- H.pylori negative at the time when the triple therapy is started

Locations (36)

Research Site

Aichi, Japan

Outcomes

Primary Outcomes

Number of Adverse Drug Reactions

Time frame: Period from the start of triple therapy to assessment of eradication, an expected average of 3 months

Secondary Outcomes

Rate of H.Pylori eradication

Time frame: Period from the start of triple therapy to assessment of eradication, an expected average of 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.